Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) – William Blair increased their Q3 2024 earnings per share estimates for Solid Biosciences in a research note issued on Wednesday, August 14th. William Blair analyst T. Lugo now expects that the company will post earnings of ($0.69) per share for the quarter, up from their prior estimate of ($0.78). The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.71) per share. William Blair also issued estimates for Solid Biosciences’ Q4 2024 earnings at ($0.63) EPS, FY2024 earnings at ($2.57) EPS, Q1 2025 earnings at ($0.68) EPS, Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($2.90) EPS.
Solid Biosciences (NASDAQ:SLDB – Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.05.
View Our Latest Report on Solid Biosciences
Solid Biosciences Price Performance
Shares of NASDAQ SLDB opened at $8.87 on Friday. Solid Biosciences has a 12 month low of $1.81 and a 12 month high of $15.05. The business’s 50 day moving average is $7.61 and its two-hundred day moving average is $9.10. The company has a quick ratio of 14.94, a current ratio of 14.94 and a debt-to-equity ratio of 0.01.
Institutional Investors Weigh In On Solid Biosciences
Institutional investors and hedge funds have recently modified their holdings of the company. RA Capital Management L.P. lifted its position in Solid Biosciences by 26.4% during the first quarter. RA Capital Management L.P. now owns 4,330,446 shares of the company’s stock worth $57,682,000 after purchasing an additional 904,160 shares during the period. Bain Capital Life Sciences Investors LLC grew its holdings in shares of Solid Biosciences by 28.9% during the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 4,034,582 shares of the company’s stock valued at $53,741,000 after purchasing an additional 904,160 shares during the last quarter. Artal Group S.A. increased its position in Solid Biosciences by 175.0% during the 1st quarter. Artal Group S.A. now owns 2,500,000 shares of the company’s stock worth $33,300,000 after purchasing an additional 1,590,781 shares in the last quarter. Janus Henderson Group PLC bought a new position in shares of Solid Biosciences in the 1st quarter valued at $23,935,000. Finally, Millennium Management LLC boosted its stake in shares of Solid Biosciences by 135.7% during the second quarter. Millennium Management LLC now owns 1,728,065 shares of the company’s stock valued at $9,798,000 after purchasing an additional 994,984 shares in the last quarter. 81.46% of the stock is owned by institutional investors.
About Solid Biosciences
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Further Reading
- Five stocks we like better than Solid Biosciences
- Consumer Staples Stocks, Explained
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What is the Australian Securities Exchange (ASX)
- MarketBeat Week in Review – 8/12 – 8/16
- Learn Technical Analysis Skills to Master the Stock Market
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.